Summit Therapeutics shares are trading lower after Citigroup downgraded the stock from Buy to Neutral.
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics shares declined following a downgrade by Citigroup from Buy to Neutral.

September 27, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Summit Therapeutics shares are trading lower after Citigroup downgraded the stock from Buy to Neutral.
The downgrade by a major financial institution like Citigroup typically signals a lack of confidence in the stock's short-term performance, leading to a decrease in investor sentiment and a drop in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100